Compare Stocks

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	$0.37 -2.6%	$0.36	$0.26 ▼ $7.80	$1.88M	0.87	188,128 shs	17,901 shs
GNPX Genprex	$2.13 -4.1%	$3.67	$2.09 ▼ $45.20	$4.07M	-0.61	74,206 shs	38,188 shs
NBSE NeuBase Therapeutics	$0.41 -4.6%	$0.71	$0.39 ▼ $4.80	$1.55M	0.83	209,781 shs	88,865 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
GLMD Galmed Pharmaceuticals	+5.63%	-10.08%	+20.01%	+11.90%	-92.38%
GNPX Genprex	0.00%	-20.50%	-34.62%	-73.56%	-94.42%
NBSE NeuBase Therapeutics	+1.07%	+3.49%	-58.80%	-30.76%	-88.21%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	4.2248 of 5 stars	3.5	5.0	0.0	4.7	0.6	0.8	1.3
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTST CannTrust	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	3.00	Buy	N/A	N/A
GNPX Genprex	3.00	Buy	$10.00	369.48% Upside
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest GNPX, CTST, NBSE, and GLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/3/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/25/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$2.75 per share	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	$4.99 per share	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	-$6.91M	-$3.26	N/A	∞	N/A	N/A	-53.29%	-44.35%	6/6/2024 (Estimated)
GNPX Genprex	-$30.86M	-$24.80	N/A	N/A	N/A	N/A	-245.62%	-185.50%	5/27/2024 (Estimated)
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTST CannTrust	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	4.81	4.81
GNPX Genprex	N/A	2.31	2.31
NBSE NeuBase Therapeutics	N/A	2.87	2.87

Ownership

Institutional Ownership

Company	Institutional Ownership
CTST CannTrust	0.03%
GLMD Galmed Pharmaceuticals	76.14%
GNPX Genprex	14.05%
NBSE NeuBase Therapeutics	12.37%

Insider Ownership

Company	Insider Ownership
CTST CannTrust	N/A
GLMD Galmed Pharmaceuticals	19.80%
GNPX Genprex	11.54%
NBSE NeuBase Therapeutics	13.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
GLMD Galmed Pharmaceuticals	4	5.05 million	4.05 million	Not Optionable
GNPX Genprex	31	1.91 million	1.69 million	Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable

GNPX, CTST, NBSE, and GLMD Headlines

Source	Headline
	NeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaq finanznachrichten.de - April 6 at 8:58 AM
	NeuBase Therapeutics Announces Receipt of Notice from Nasdaq globenewswire.com - April 5 at 4:05 PM
	Once-promising Pittsburgh biotech firm shutting down for good technical.ly - March 27 at 8:33 PM
	Why Neubase Therapeutics (NBSE) Shares Are Nosediving msn.com - March 27 at 10:32 AM
	NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare movers msn.com - March 26 at 10:47 AM
	Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today? investorplace.com - March 26 at 9:08 AM
	NeuBase Therapeutics sets shareholder meeting on dissolution plan bizjournals.com - March 25 at 7:44 PM
	NeuBase Therapeutics Inc edition.cnn.com - February 26 at 9:46 AM
	NeuBase Therapeutics, Inc. (NBSE) finance.yahoo.com - February 20 at 1:40 PM
	NeuBase Therapeutics Inc (O7P.BE) ca.finance.yahoo.com - January 20 at 12:17 AM
	Monitoring NeuBase Therapeutics Inc (NBSE) after recent insider movements knoxdaily.com - January 1 at 2:48 PM
	CMU halts licensing agreement with NeuBase Therapeutics bizjournals.com - December 22 at 7:16 PM
	Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance finance.yahoo.com - November 27 at 10:19 AM
	NeuBase Therapeutics Inc NBSE morningstar.com - November 6 at 11:41 PM
	NeuBase Therapeutics: Other Events cbonds.com - October 21 at 8:32 AM
	NeuBase Therapeutics, Inc. (NBSE.MX) finance.yahoo.com - October 6 at 8:56 AM
	NeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. Wainwright knoxdaily.com - September 20 at 6:31 PM
	Massive Insider Trade At NeuBase Therapeutics benzinga.com - September 12 at 3:51 PM
	NeuBase falls after largest shareholder disposes of part stake msn.com - September 12 at 3:51 PM
	NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder finance.yahoo.com - September 8 at 11:10 AM
	Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today? markets.businessinsider.com - September 6 at 9:07 AM
	NBSE’s short interest falls to 41130.0 shares knoxdaily.com - August 25 at 4:34 PM
	Analysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA) markets.businessinsider.com - August 16 at 7:45 AM
	NeuBase Therapeutics (NASDAQ: NBSE) fool.com - August 6 at 6:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CannTrust

NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Galmed Pharmaceuticals

NASDAQ:GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Genprex

NASDAQ:GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial